Story image for keytruda hodgkin lymphoma from Zacks.com

Application (sBLA) – the second this week – for its anti-PD-1 therapy, Keytruda, has been accepted for priority review by the FDA.

This time, the company is looking to expand the label for the treatment of patients with refractory classical Hodgkin lymphoma (cHL) or who had relapsed after three or more prior lines of therapy.

Merck’s shares are up 15% this year comparing favorably with a decline of 8.1% for the Zacks classified Large-Cap Pharma industry backed by consistently strong earnings results and regular positive news flow and regulatory updates.

MERCK & CO INC Price

 

MERCK & CO INC Price | MERCK & CO INC Quote

 

https://www.zacks.com/stock/news/241112/mercks-keytruda-gets-priority-review-for-hodgkin-lymphoma

Leave a Reply